An observational study in Breast Cancer - Female and Fertility, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Active, not recruiting at 3 sites in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.
Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 172nd largest by planned enrollment of the 407 observational ones that give a count, is one of 237 that started in 2025, is one of 407 observational ones, reaches primary completion later than 459 of the 1,063 other live ones, and was the 1,895th registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 40 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,928 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 279 · Phase 2 641 · Phase 3 371 · Phase 4 51
First in 1997; this study’s year is marked. 237 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,519 interventional studies, 240 across the 407 observational. Of the 445 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
488 of 1,928 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 104 studies on the registry; 70 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 8 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
250 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 250 to your calendar (.ics) → With an account.
Among the 1,928 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study is to learn about the fertility outcomes and decision after breast cancer diagnosis, and the current status of fertility consultation and decision support in young women diagnosed with breast cancer in China.
This study will include female patients aged 18-40 years who were diagnosed with breast cancer between January 2013 and December 2023 at one of three participating centres in China: the Second Affiliated Hospital of Zhejiang University School of Medicine, Jilin Cancer Hospital, and Hangzhou First People's Hospital.
Eligible patients must have complete medical records and no child before cancer diagnosis.
Patients with stage IV disease at diagnosis, those with pre-existing infertility factors, or those with other malignancies, will be excluded. Patients who decline to participate or cannot be contacted for follow-up will also be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had no live birth after diagnosis.
Other: No intervention (observational study)
Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had at least one live birth after diagnosis.
Other: No intervention (observational study)
This is an observational study. The study is based on the real-world conditions, and doesn't have any intervention.
Childbearing after breast cancer diagnosis
The investigators will follow up with patients who had not given birth before their cancer diagnosis, to establish whether they had given birth by the end of follow-up. It will be assessed by patient self-report during follow-up and available medical records. The outcome will be recorded as a binary variable (yes/no).
Time frame: Up to 2026
Fertility preservation measures uptake
The investigators will calculate the proportion of patients who underwent fertility preservation procedures in cases vs. controls.
Time frame: up to 2026
Multidisciplinary collaboration involvement
The investigators will calculate the proportion of patients with multidisciplinary team discussion or referral involving reproductive medicine, gynecology, or fertility specialists.
Time frame: up to 2026
Ran from Oct 2025 to primary completion in Sep 2026, 10 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →